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Abstract 
Background: Management algorithms for adult severe traumatic brain injury (sTBI) were omitted in later editions of 
the Brain Trauma Foundation’s sTBI Management Guidelines, as they were not evidence-based.
Methods: We used a Delphi-method-based consensus approach to address management of sTBI patients undergo-
ing intracranial pressure (ICP) monitoring. Forty-two experienced, clinically active sTBI specialists from six continents 
comprised the panel. Eight surveys iterated queries and comments. An in-person meeting included whole- and 
small-group discussions and blinded voting. Consensus required 80% agreement. We developed heatmaps based on 
a traffic-light model where panelists’ decision tendencies were the focus of recommendations.
Results: We provide comprehensive algorithms for ICP-monitor-based adult sTBI management. Consensus estab-
lished 18 interventions as fundamental and ten treatments not to be used. We provide a three-tier algorithm for 
treating elevated ICP. Treatments within a tier are considered empirically equivalent. Higher tiers involve higher risk 
therapies. Tiers 1, 2, and 3 include 10, 4, and 3 interventions, respectively. We include inter-tier considerations, and 
recommendations for critical neuroworsening to assist the recognition and treatment of declining patients. Novel ele-
ments include guidance for autoregulation-based ICP treatment based on MAP Challenge results, and two heatmaps 
to guide (1) ICP-monitor removal and (2) consideration of sedation holidays for neurological examination.
Conclusions: Our modern and comprehensive sTBI-management protocol is designed to assist clinicians manag-
ing sTBI patients monitored with ICP-monitors alone. Consensus-based (class III evidence), it provides management 
*Correspondence:  chesnutr@uw.edu 
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Introduction
The Brain Trauma Foundation (BTF) Guidelines for the 
Management of Severe Traumatic Brain Injury (sTBI) 
[1] have been widely incorporated into practice and 
associated with a reduction in mortality from sTBI [2]. 
The first two editions [1, 3] included popular treatment 
algorithms. However, because different sTBI treatments 
have been studied in isolation, almost no evidence exists 
regarding their relative efficacy, sequential ordering or 
combination as would be required to create evidence-
based treatment protocols [4]. Later editions thus rec-
ognized that these algorithms could not be based on 
published evidence and omitted them [5, 6], to the 
expressed disappointment of many readers. In response 
to algorithm requests and the paucity of high-quality evi-
dence for sTBI management algorithms, we here use a 
consensus approach to develop a management algorithm 
for sTBI that will be useful across a variety of manage-
ment environments, with the condition that the sTBI 
patient is admitted to an ICU with an intracranial pres-
sure monitor in situ.
We present a series of consensus-based algorithms for 
adult sTBI management. Our consensus working group 
(CWG) established 18 interventions as fundamental to 
sTBI care and ten treatments not to be used. It also estab-
lished a three-tier algorithm focused on treating elevated 
ICP wherein higher tiers involve therapies with higher 
risk. We suggest considerations to address when advanc-
ing from lower to higher tiers and recommendations for 
critical neuroworsening aimed at assisting the recogni-
tion, workup, and treatment of declining patients. Novel 
elements include guidance for autoregulation-based ICP 
treatment and the performance of MAP Challenges, as 
well as two sets of heatmaps to guide (1) consideration of 
sedation holidays to facilitate neurological examination 
and (2) ICP-monitor removal.
Methods
Forty-two physicians comprised the CWG for the Seat-
tle Severe Traumatic Brain Injury Consensus Con-
ference (SIBICC) algorithm. The panel included ten 
neurointensivists, 23 neurosurgeons, five neurologist/
neurointensivists, two trauma surgeons, and two emer-
gency medicine specialists. We based panel selection 
on (a) > 10  years clinical experience in sTBI; (b) cur-
rent, active involvement in acute care management of 
sTBI patients; (c) representation of involved disciplines; 
(d) geographic diversity; and (e) ability to commit time 
to the algorithm development process. We calculated 
panel size based on logistic considerations. Panelists 
completed conflict of interest forms relevant to sTBI 
management. There were no conflicts mandating rec-
usal of any participant. In advance of the meeting all 
participants were provided with electronic copies of all 
manuscripts taken as evidence for the 4th edition Brain 
Trauma Foundation Guidelines for the Management of 
Severe TBI organized by chapter.
The expressed focus of the effort was to design a man-
agement algorithm that would be acceptable to the panel 
and amenable to application in both neurological and gen-
eral ICUs by physicians not specialized in neurointensive 
care. Prior to the meeting, the CWG completed eight web-
based surveys (SurveyMonkey Inc., San Mateo, California, 
USA, www.surve ymonk ey.com) to determine the algo-
rithm design and focus, explore definitions and thresh-
olds, operationally define treatment modalities, evaluate 
acceptability and tier assignments of treatment modalities, 
etc. We combined voting results with panelists’ comments 
to iterate these surveys to maximize consensus and define 
areas requiring focus at the in-person meeting.
Two special surveys addressed the timing of ICP moni-
tor removal and the use of sedation holidays for exami-
nations. Early voting using discrete-elements did not 
progress toward resolution of these multivariate issues, 
so they were assembled into matrices, each cell of which 
represented a concatenation of multiple individual 
clinical indicators. By combining individual panelist’s 
responses and color-coding the results using a traffic-
light model (red-yellow-green), we constructed heatmaps 
to guide decision-making. We modified the Marshall CT 
classification [7] of post-operative imaging for this exer-
cise. The post-surgical CT scans of patients having an 
evacuated mass lesion (EML) were additionally classi-
fied as if they had not had surgery (i.e., DI I–IV) and this 
ranking was appended to the EML label (e.g., EML/DI 
IV) in the heatmaps. We did this to increase the sensitiv-
ity of post-operative images to indicators of intracranial 
hypertension for this exercise.
The in-person SIBICC meeting occurred from the 
5th to 7th of April 2019 in Seattle, Washington, USA. 
We used anonymous electronic voting and vote analysis 
(Electronic Media Services Inc., Gig Harbor Washington, 
USA, www.elect ronic meeti ngser vices .com). Professional, 
independent non-physician moderators facilitated group 
recommendations based on combined expert opinion. It reflects neither a standard-of-care nor a substitute for 
thoughtful individualized management.
Keywords: Brain injury, Head trauma, Algorithm, Protocol, Consensus, Intracranial pressure, Tiers, Seattle, SIBICC
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discussions. We used small group sessions to address 
complex issues, with the whole CWG modifying and vot-
ing on small-group recommendations. All recommenda-
tions were incorporated verbatim into the final product. 
Unless specifically modified by the CWG, we limited the 
voting cycle to three iterations, interspersed with discus-
sions. An element formed part of the final recommenda-
tions only if it achieved 80% agreement as “acceptable” 
(voting threshold) by at least 80% of the panelists (a quo-
rum) in the confidential electronic voting. Unresolved 
issues are reported as such (Supplemental Material).
Donations solicited from industry and other inter-
ested parties funded this meeting. In return, they were 
allowed to silently observe the conference, without any 
interaction with the panelists or the process. No donors 
or other outside parties influenced any portion of these 
recommendations.
Results
Consensus-efforts generated a list of interventions 
viewed as fundamental to the care of sTBI patients and 
which should ideally be in place early in the course of 
care (Fig. 1). The CWG also generated a list of treatments 
that should not be used in the care of patients with severe 
TBI (Table  1), except in special circumstances. They 
developed a three-tier algorithm focused on the manage-
ment of ICP elevation following severe TBI (Fig. 2). The 
CWG provided inter-tier recommendations (Fig. 2) and 
guidance on critical neuroworsening (Fig. 3) to assist in 
evaluating and managing patients requiring increased 
therapeutic intensity. Heatmaps provide the CWG’s 
consensus opinion on when it is safe to remove an ICP 
monitor (Fig. 4) and the safety of performing a sedation-
vacation aimed at obtaining an accurate neurological 
examination (Fig. 5).
Discussion
Sufficient research-based literature on individual ICP 
treatments exists to allow creation of an evidence report 
[6]. Unfortunately, there is insufficient research on the 
amalgamation of these individual treatments into a 
Fig. 1 Consensus-based basic severe traumatic brain injury care for patients with an ICP monitor in situ. These are basic treatments recommended 
as fundamental to the care of patients with sTBI, to be initiated (“Expected interventions”) or considered (“Recommended interventions”) upon ICU 
admission of a patient with an ICP monitor, regardless of the monitored pressure. CO2 carbon dioxide, CPP cerebral perfusion pressure, Hg hemo-
globin, HOB head of bed, ICP intracranial pressure, ICU intensive care unit, spO2 arterial oxygen saturation
Table 1 Treatment not recommended for  use in  the man‑
agement of severe traumatic brain injury (when only ICP is 
monitored)
CPP cerebral perfusion pressure, ICP intracranial pressure, kPa kiloPascals, PaCO2 
arterial partial pressure of carbon dioxide
Mannitol by non-bolus continuous intravenous infusion
Scheduled infusion of hyperosmolar therapy (e.g., every 4–6 h)
Lumbar CSF drainage
Furosemide
Routine use of steroids
Routine use of therapeutic hypothermia to temperatures below 35 °C 
due to systemic complications
High-dose propofol to attempt burst suppression
Routinely decreasing  PaCO2 below 30 mmHg/4.0 kPa
Routinely raising CPP above 90 mmHg
1786
management algorithm to allow evidence-based devel-
opment of a treatment approach. Since daily care con-
sists of amalgamating individual treatments into a care 
plan, leaving this process to individual, non-expert 
practitioners without specific guidance is undesir-
able. Despite its limitations and weaknesses, the Delphi 
method remains the best current methodology for devel-
oping recommendations from expert consensus. As 
an evidentiary basis for prioritizing, sequencing, and 
combining sTBI treatments does not currently exist, 
we applied the Delphi method rigorously to this work, 
concomitantly recognizing the relative weakness of this 
approach.
Protracted specialist experience provides the expert 
practitioner repeated feedback on their manner of 
combining individual therapies. Although neither con-
ditions nor outcomes are rigorously controlled, the 
impact of many repeated exposures to the influence of 
their therapeutic approach on short-term results (such 
as acute ICP control) should bestow a form of wisdom 
(“Medicine-Based Evidence”; the time-tested experi-
ence of an individual practitioner). An individual’s wis-
dom is likely confounded by factors such as personal 
biases, technical idiosyncrasies, the care environment, 
patient population and injury demographics, etc. The 
concept of a consensus conference is to combine a large 
Fig. 2 Consensus-based algorithm for the management of severe traumatic brain injury guided by intracranial pressure measurements. Upper 
right box presents the principles for navigating through the treatments and tiers. Lower tier treatments are viewed as having a more favorable side 
effect profile than higher tiers and generally should be employed first. Inter-tier recommendations encourage patient reassessment for remediable 
causes of treatment resistance. See text for details. CPP cerebral perfusion pressure, EEG electroencephalogram, EVD external ventricular drain, ICP 
intracranial pressure, kPa kiloPascals, MAP mean arterial pressure, PaCO2 arterial partial pressure of carbon dioxide
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cohort of such experts and determine where their expe-
riences overlap. As it is unlikely that individual-specific 
confounding factors will be shared, areas where there 
is general agreement should reflect a degree of clinical 
efficacy. The inclusion of multiple specialties, interna-
tional sites, and varying practices should improve gen-
eralizability. We used this theoretical framework here 
to construct this set of recommendations.
Even with a large panel, blinded voting, and much 
discussion, such a process lacks rigor. As well, the 
observations on which the clinical wisdom is based 
primarily involve only ICP control and short-term 
clinical outcome. Therefore, the reader should con-
sider these recommendations as a suggested treatment 
method without proven superiority over other appli-
cable methods. Although primarily targeted at those 
with limited experience in monitor-based sTBI man-
agement, all practitioners involved in critical care treat-
ment of sTBI patients may find these recommendations 
useful. They represent a safe and modern approach to 
sTBI care. They are not a standard of care or even the 
best treatment approach in a given instance. They are 
not legally binding. They are not designed as quality 
assurance monitoring tools. They do not represent the 
approach of any individual CWG member and should 
never be substituted for thoughtful clinical judgment. 
Hopefully, future scientific testing can increase the 
rigor of these recommendations and quantify their effi-
cacy as steps toward establishing evidence-based algo-
rithm development.
Derived by a large, international, multi-specialty con-
sensus group through a rigorous Delphi-based con-
sensus process, these recommendations are designed 
to augment other current management-related offer-
ings such as the American College of Surgeons-Trauma 
Quality Improvement Program (ACS-TQIP) document 
[8], into which these recommendations are currently 
being integrated by the ACS Committee on Trauma 
(ACS-COT).
Use of these recommendations in clinical practice
Conditions of tiered treatment
The use of tiers attempts to balance the benefits and 
efficacy of an agent against risks inherent to its use 
(Fig.  2). General clinical management is considered 
Tier Zero. Treatment of intracranial hypertension will 
generally begin at Tier-one. Movement to higher tiers 
reflects increasingly aggressive interventions. Treat-
ments in any given tier are considered equivalent, with 
selection of one treatment over another based on indi-
vidual patient characteristics and physician discretion. 
During any given episode being addressed, multiple 
Fig. 3 Critical neuroworsening and its management. SIBICC defini-
tion (upper box), response (middle box) and a list of suggested 
differential diagnoses (bottom) surrounding critical neurological 
deterioration (critical neuroworsening). CNS central nervous system, 
GCS Glasgow Coma Scale, ICP intracranial pressure
Fig. 4 Consensus views on the safety of intracranial pressure monitor removal in patients with acceptable ICP (no longer requiring active ICP 
management). The heatmap represents a summary analysis of the likelihood of each CWG member to remove the ICP monitor under differing con-
ditions of stable pupillary status, GCS [20] motor score, modified CT classification (see “Methods”), duration of acceptable ICP, and degree of treat-
ment previously required for any intracranial hypertension (none, Tier 1, or Tier 2 or 3). Green, yellow, and red indicate “safe to proceed”, “consider 
proceeding with caution” and “do not proceed”, respectively, with transitional shades reflecting intermediate trends. To use, choose the heatmap 
representing the ICP treatment history, then the appropriate status cell reflecting categorization of the patient in terms of the variables presented. 
The color in the relevant cell reflects the tendency of the CWG to withdraw the ICP monitor in that circumstance. It is up to the treating physician to 
consider the value of that tendency in making the final decision. AP abnormal pupils, CT computed tomography, DI diffuse injury as defined in the 
Marshall CT Head Score, GCS Glasgow Coma Scale, EML evacuated mass lesion as defined in the Marshall CT Head Score, ICP intracranial pressure, 
NP normal pupils
(See figure on next page.)
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items from a single tier can be trialed individually or 
in combination with the goal of a rapid response. The 
provider should maintain awareness of the duration of 
any episode and consider moving to more aggressive 
interventions in a higher tier quickly if the patient is 
not responding. In some cases, it might be preferrable 
to skip one or more tiers (e.g., choosing to decompress 
a patient with midline shift due to hemispheric swell-
ing and very high initial ICP). No individual agent or 
combination thereof is critical to success in managing 
TBI. Clinical judgment must always determine the final 
management strategy.
Tier‑zero
Tier-zero (Fig.  1) recommendations apply to sTBI 
patients with an ICP monitor in  situ who are admit-
ted to an ICU. Management recommendations for sTBI 
patients without ICP monitoring are published elsewhere 
[9]. The goal of Tier-zero is to establish a stable, neuro-
protective physiologic baseline regardless of eventual ICP 
readings. Tier-zero sedatives and analgesics target com-
fort and ventilator tolerance rather than ICP. Tempera-
ture management targets avoiding fever (defined by our 
CWG as core temperature > 38  °C). Consistent with the 
BTF Guidelines [6], the minimal cerebral perfusion pres-
sure (CPP) threshold is 60 mmHg.
Tier‑one through tier‑three (treatment 
of established intracranial hypertension)
Tier‑one
Tier-one (Fig. 2) represents the first foray into managing 
intracranial hypertension. The CWG adopted the BTF 
Guidelines’ recommendations for initial ICP and cere-
bral perfusion pressure (CPP) thresholds (22 mmHg and 
60  mmHg, respectively) [6]. Tier-one sedative or anal-
gesic manipulation focuses on lowering ICP. The CWG 
decided not to recommend one hypertonic solution 
over the other, or to recognize different dosing levels 
(e.g., low and high dose) for either. After some discus-
sion, they recommended using the same upper limits for 
serum sodium and osmolality for both agents.
When ICP is monitored using ventriculostomy, the 
CWG recommended CSF drainage as a Tier-one treat-
ment. If an intraparenchymal device is used, consider 
ventriculostomy to enable CSF drainage. As subclini-
cal seizure activity can cause intracranial hypertension, 
consider EEG monitoring and reconsider 1  week of 
prophylactic anti-epileptic drugs if not routinely used.
Tier‑two
The hazards of routine neuromuscular blockade [10] 
prompted discussion regarding its position in Tier-
two versus three. The decision to place it at Tier-two 
includes a recommendation for basing continued 
administration on efficacy demonstrated during a trial 
period and to discontinue it as soon as possible.
Known risks of hyperventilation in sTBI [6] and fre-
quent use of  PbtO2 monitoring at many panelists’ centres 
prompted caution in recommending even mild hyperventi-
lation when brain oxygenation monitoring is not employed. 
To allow the maximum number of acceptable tools to those 
employing only ICP monitoring; however, the CWG recom-
mended mild hyperventilation  (PaCO2 32–35 mmHg/4.3–
4.7 kPa) as a Tier-two treatment. They did not support lower 
 PaCO2 levels and recommended against routine hyperventi-
lation to below 30 mmHg/4.0 kPa.
As increasing CPP can lower ICP if static pressure 
autoregulation (sPAR) is intact [11–13], the CWG rec-
ommended a simplified method of testing sPAR sta-
tus based on that of Rosenthal et al. [14]. When CPP is 
above the lower breakpoint of sPAR and is then raised, 
the vasoconstriction attendant to active autoregulation 
decreases cerebral blood volume. This can be observed if 
the responses are trended, or by comparing the relevant 
parameters (i.e., ICP, MAP, and CPP) at the beginning 
and end of the test. As MAP elevation with disrupted 
sPAR may worsen intracranial hypertension, a practi-
tioner capable of interpreting the results and halting 
the study should perform the test. If the trial is positive, 
judgment is required as to whether the benefit of the ICP 
decrease justifies the risks inherent to pharmacologically 
raising MAP. Cautious interpretation and application of 
the results of the MAP Challenge are recommended, as 
(See figure on next page.)
Fig. 5 Consensus views on the safety of performing a sedation holiday aimed at obtaining an accurate neurological examination in patients whose 
ICP is controlled under different degrees of active management. The heatmap represents a summary analysis of the likelihood of each panelist 
to halt sedation to get an optimized neurological exam under differing conditions of stable pupillary status, GCS [20] motor score, modified CT 
classification (see “Methods”), duration of acceptable ICP with ongoing treatment, and degree of treatment previously required for any intracranial 
hypertension (none, Tier 1, or Tier 2 or 3). Green, yellow, and red indicate “safe to proceed”, “consider proceeding with caution” and “do not proceed”, 
respectively, with transitional shades reflecting intermediate trends. To use, choose the heatmap representing the ICP treatment history, then the 
appropriate status cell reflecting categorization of the patient in terms of the variables presented. The color in the relevant cell reflects the tendency 
of the CWG to perform a sedation holiday in that circumstance. It is up to the treating physician to consider the value of that tendency in making 
the final decision. AP abnormal pupils, CT computed tomography; DI diffuse injury as defined in the Marshall CT Head Score, GCS Glasgow Coma 
Scale, EML evacuated mass lesion as defined in the Marshall CT Head Score, ICP intracranial pressure, NP normal pupils
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the test results may not be simple to interpret and the 
status of cerebral pressure autoregulation may not be 
stable.
The MAP Challenge is performed under stable condi-
tions; to prevent confounding, no other active changes 
in care should be made during the challenge (includ-
ing adjustments in sedation, analgesia, EVD drain-
age or other physiological parameters). To perform the 
challenge:
  • Record baseline monitor parameters at the beginning 
of the challenge (e.g., ICP, MAP and CPP).
  • Initiate or titrate a vasopressor to increase the MAP 
by 10 mmHg for up to 20 min.
  • Observe the interaction between the MAP, ICP, and 
CPP during the challenge.
  • Record monitor parameters at the end of the chal-
lenge.
  • Evaluate the observed responses and recorded values 
for evidence of sPAR status. Disrupted sPAR will pre-
sent as a sustained increase in ICP with MAP eleva-
tion.
  • Adjust the target MAP back to baseline (disrupted 
sPAR) or to the chosen new, elevated target (intact 
sPAR).
Tier‑three
Tier-three treatments have the greatest associated risks. 
The initiation of high-dose barbiturate therapy should be 
based on the response to a test dose. The CWG recom-
mended EEG monitoring if barbiturates are continued 
and not titrating the dose upwards if burst suppression 
occurs, as further reduction in ICP is not anticipated 
and toxicity increases with dose. The endpoint of barbi-
turate treatment is ICP control not serum levels or EEG 
response. Hypotension must be avoided. The CWG 
supported use of mild hypothermia (35–36  °C) but not 
routine therapeutic hypothermia to below 35  °C due 
to systemic complications. The CWG recommended 
decompressive craniectomy with recognition of the indi-
cations and hazards demonstrated by recent RCTs [6, 15, 
16].
Not used
The CWG recommended against the use of ten manage-
ment items for treating established intracranial hyper-
tension (Table  1; ≥ 80% consensus). Some are specific 
pharmacologic agents or means of administering them. 
There are also specific physiologic parameters viewed as 
unsafe to exceed during treatment. The panel agreed that 
there may be circumstances where listed items might be 
reasonably used by an experienced and expert clinician in 
infrequent and carefully considered situations.
The CWG did not support hypothermia below 35  °C. 
Although hypothermia can lower ICP, there are no defin-
itive outcome-based studies supporting recommenda-
tions. The evidence against its neuroprotective efficacy 
and demonstrated associated morbidity [17] were cited 
as reasons not to include it until studies on hypothermia-
mediated treatment of intracranial hypertension and 
recovery become available.
Inter‑tier recommendations
Stepping to a higher tier is a potential indicator of 
increased disease severity. As higher tiers represent 
interventions with increased associated risks, the CWG 
recommends reassessing the patient’s basic intra- and 
extra-cranial physiologic status and reconsidering the 
surgical status of intracranial mass lesions (e.g., contu-
sions) not previously considered operative. If the patient 
is at a non-specialist centre at the point of upward tier 
advancement, the CWG recommended considering con-
sultation with and potential transfer to a TBI center with 
increased resources if possible within the regional health-
care environment. When desired, transfer is best com-
pleted before clinical decline precludes it.
Critical neuroworsening
Critical neuroworsening represents a specific situation of 
critical deterioration requiring emergent evaluation and 
management. Neuroworsening was first defined retro-
spectively as a potential intermediate-outcome variable 
for TBI trials [18], it was adapted as a clinical variable for 
the BEST:TRIP trial [19] and subsequent management 
studies for limited resource environments [9]. The CWG 
adapted it here, terming the clinical definition “Critical 
Neuroworsening”, to promote its recognition as a critical 
event and guide expeditious evaluation and consideration 
of empiric therapy.
Weaning ICP treatment
Sedation holiday heatmaps
The CWG recognized the balance between obtaining the 
most accurate (non-sedated) neurological examination 
of sTBI patients and the hazards of temporarily halting 
sedation to perform these examinations. Survey attempts 
at gaining consensus on relative and absolute contrain-
dications were unsuccessful. The CWG therefore chose 
to construct matrices representing the most relevant 
decision variables under differing intracranial hyperten-
sion scenarios to recognize the distribution of the panel’s 
opinions. The resulting heatmaps reflect the variability 
among expert clinicians in the perceived safety of seda-
tion holidays in monitored sTBI patients. Using these 
decision-support matrices involves first determining 
which cell represents the patient in question. In situations 
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where there are no other contraindications, green or 
“greenish” status supports sedation holiday use in line 
with the CWG’s procedural recommendations. Red or 
“reddish” status represents relative recommendation 
against sedation holiday performance. The large areas 
appearing “yellowish” represent areas where the recom-
mendations regarding proceeding are qualified, leaving 
to the clinician to decide if the current risk:benefit ratio 
might justify a sedation holiday. An alternative approach 
under “yellowish” conditions is to determine those fac-
tors that might be altered to shift the patient to a more 
highly recommended status. In all cases, however, the 
final decision is entirely up to the managing physician, 
with the heatmap serving only as an ancillary “consulta-
tion” from the CWG.
Procedural recommendations focus on minimiz-
ing risks and enhancing the utility of sedation holidays. 
Coordinating timing and optimizing the opportunity for 
all involved parties to be present (e.g., Intensivist, Neu-
rosurgeons, etc.) maximizes the safety and interpretation 
of sedation holidays under all conditions. Finally, finding 
a favorable exam during the sedation holiday offers an 
opportunity to initiate sedation tapering.
ICP monitor removal heatmap
There is little literature regarding how long ICP should 
be acceptable before monitoring is discontinued. Marked 
variability in CWG survey results and lack of progression 
toward resolution over repeated surveys mimicked the 
sedation holiday conditions. Following the same logic, 
the CWG created heatmaps for ICP monitor removal. 
Using them for decision support again involves choos-
ing the relevant heatmap and then the appropriate cell. 
The implications of the associated color parallel those 
described for the sedation holiday. Inspection of the 
heatmap trends confirms the marked variation among 
panelists. They suggest that 72  h of acceptable ICP is 
almost universally accepted whereas removal at 24  h is 
recommended only for patients with fairly benign CTs 
and favorable exams. The therapeutic intensity required 
prior to acceptable ICP and the Glasgow Coma Scale 
[20] motor score also appear to be strong influences on 
this decision. There is marked variability in the relative 
comfort with following the clinical examination versus 
continued monitoring in sTBI patients without contin-
ued intracranial hypertension. The value of the heatmap 
represents moderation rather than resolution of this 
controversy.
Summary
The goal of these SIBICC recommendations is to fill the 
void between the currently published evidence-based 
guidelines and clinical practice, using modern medi-
cine-based-evidence to guide algorithm construction. 
Such algorithms provided a bridge between evidence-
based analyses of individual treatments and the integra-
tion of these modalities into the management approach 
that is necessary at the bedside. The 42 clinically active 
global thought leaders with long-term experience in 
acute sTBI management who comprise the CWG used 
a Delphi-based consensus approach to produce a form 
of Medicine-Based-Evidence to facilitate the common 
situation of sTBI management at non-TBI centers. As 
consensus-based recommendations, they constitute the 
lowest level of evidence (Class III in the BTF Guidelines 
methodology [6]). Recognizing that these are recommen-
dations—a form of multi-physician curbside consult—
they are aimed at clinicians not specifically expert in the 
management of sTBI or those considering initiating ICP 
monitoring. They may be clinically adopted, adapted, 
referenced, or otherwise considered by individual physi-
cians or medical centres. They may serve as useful tools 
for research design and should be subjected to analysis 
using comparative effectiveness research tools as well as 
trials. They are offered as guidance only, as a first attempt 
at filling a gap in the current clinical literature.
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Hg: Hemoglobin; HOB: Head of bed; ICE: Imaging and clinical examination; 
ICP: Intracranial pressure; ICU: Intensive care unit; kPa: KiloPascals; MAP: Mean 
arterial pressure; NP: Normal pupils; PaCO2: Arterial partial pressure of carbon 
dioxide; PbtO2: Partial pressure of brain tissue oxygen; spO2: Arterial oxygen 
saturation.
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